[Two cases of pseudomyxoma peritonei that responded to intraperitoneal administrations of a combined CDDP, 5-FU and

A Sasaki1, M Terashima, K Okamoto

  • 1Dept. of Surgery I, School of Medicine, Iwate Medical University.

Insights

Pseudomyxoma peritonei treatment remains challenging. This study shows promising results with a combined postsurgical chemotherapy regimen of cisplatin (CDDP), 5-fluorouracil (5-FU), and mitomycin C (MMC) in two patients.

Area of Science:

  • Oncology
  • Gastroenterology
  • Surgical Oncology

Background:

  • Pseudomyxoma peritonei (PMP) is a rare malignancy characterized by mucinous ascites and peritoneal seeding.
  • Current treatment options for PMP have limited efficacy, often resulting in a poor prognosis even after surgical debulking.
  • There is a critical need for effective postsurgical therapies to improve outcomes for PMP patients.

Related Concept Videos